

Press Release

July 3, 2020

2cureX AB expands its Board of Directors with Michael Lutz and Nils Brünner

Michael Lutz and Nils Brünner have been elected to the Board of Directors in connection with the Extraordinary General Meeting on July 2, 2020. Michael Lutz and Nils Brünner will bring important complementary competencies and international experiences to the 2cureX Board at a landmark moment of launching indiTreat®. At the same time Timm Jessen, founding partner of 2cureX has announced that he will step down from the Board for personal reasons.

In connection with the upcoming commercialization of IndiTreat®, it has been proposed and decided to expand the Board of Directors from 5 to 6 members.

Michael Lutz is an experienced international biotech entrepreneur who has spent the last 15 years at executive management positions with several US and European Life Sciences companies which he successfully established or built-up to a successful exit. Michael is currently CEO of HepaRegeniX GmbH (Tübingen, Germany) and also serves on the Strategic & Scientific Advisory Board for Noscendo GmbH

Nils Brünner is medical oncologist with extensive experience both as clinician and as biotech entrepreneur. Nils is a highly recognized scientist with more than 370 scientific papers especially in the field of translational cancer research. Nils is co-founder and CEO of Scandion Oncology A/S where he, through development of a first in class drug candidate against drug resistance in cancer patients, has moved the company to be one of the most successful listed companies at Stockholm Stock Exchange.

Nils Brünner says: *“I am delighted to be asked to join the 2cureX Board. I have for more than 30 years been involved in individualizing cancer treatment and not the least been interested to find tools that can help alleviating drug resistance in cancer treatment. I believe that the functional test, IndiTreat is filling a gap in the decision-making process of matching drug treatment with patients. I look forward to be part of 2cureX’s journey moving forward”.*

Michael Lutz further comments: *“To successfully introduce an In-Vitro-Diagnostics (IVD) product into the clinical environment requires a strong product performance, understanding of the decision-making process in different markets, regulatory understanding and a comprehensive network among clinical institutions and distributors. I look forward to bring my experience in the global market for innovative IVD products to the strategic development of 2cureX”.*

Povl-Andre’ Bendz, Chairman of 2cureX says: *“It is a pleasure to welcome Dr. Lutz and Dr. Brünner to 2cureX’s Board of Directors. 2cureX is at an exciting phase on its journey towards a full fledged Medtech company with paradigm-shifting products. Strong clinical expertise and IVD market knowledge provided by our new Board members are essential components of this development of the company. I will also take the opportunity to thank Timm Jessen, who from personal reasons, has decided to step down from the Board. Timm was instrumental in providing 2cureX a foothold in Germany. I wish Timm the best of luck”.*

The Board of Directors will subsequently be composed of:

Name	Role	Elected	Nationality
Povl-Andre Bendz	Chairman	2014	DK
Camilla Huse Bondesson	Board member	2019	SE
Nils Br�nner	Board member	2020	DK
J�rger Drejer	Board member	2017	DK
Michael Lutz	Board member	2020	DE
Ole Thastrup	Board member	2006	DK

For more information about 2cureX

Ole Thastrup, Chief Executive Officer

E-mail: ot@2curex.com

Telephone: +45 22 11 53 99

www.2curex.com

Certified Adviser

Redeye AB

Telephone: +46 8 121 576 90

E-mail: certifiedadviser@redeye.se

2cureX has developed the IndiTreat[®] (Individual Treatment) test. IndiTreat[®] establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat[®] is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, United Kingdom and Sweden.

IndiTreat[®] is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat[®] becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).